Malaysia’s health ministry welcomes medical cannabis clinical studies

WhatsAppWhatsAppFacebookFacebookTwitterTwitterPinterestPinterestRedditRedditGmailGmailShareShare

Last updated on August 3rd, 2022 at 12:31 pm

As there are currently no clinical trials being conducted on products containing cannabis extract for medical purposes, the Health Ministry in Malaysia welcomes applications to conduct clinical trials on these products. Deputy Health Minister Dr. Noor Azmi said on Thursday that such trials are not being carried out at this time, July 28th.

In response to a query from the Malaysian parliament, he stated that the Dangerous Drugs Act of 1952, the Poisons Act of 1952, and the Sale of Drugs Act of 1952 all make it possible for cannabis extract to be provided, imported, sold, and used for medical purposes, research, or clinical trials.

Also Read: The 10 Richest People in Malaysia

According to Dr. Azmi, businesses that are in possession of sufficient scientific evidence demonstrating the usefulness of products containing cannabis extract for medical purposes are eligible to make an application to the Drug Control Authority of Malaysia (DCA) in order to register those products.

According to the advertising, companies who have medicinal cannabis products that have been approved in other countries are eligible to submit an application in order to have their products registered and promoted in Malaysia.

Related Posts

These remarks were given in response to a query from Syed Saddiq Syed Abdul Rahman (Muda-Muar), who asked MoH to provide the most recent information regarding the legalization and use of medical cannabis in Malaysia.

“The MOH does not reject studies on the effectiveness of medical cannabis; it is time we follow the steps of 40 countries that have used it to treat diseases including cancer, depression, and epilepsy; we are ready to look at this,” he said in a statement.

According to Dr. Azmi, a proposal to separate the legal interpretations of cannabis, medical cannabis, and hemp will depend on the conclusions of the special committee that has been entrusted to research and establish the path of the industry’s development.

“Therefore the need to amend the Dangerous Drugs Act 1952 in connection with the control of cannabis and hemp, including creating separate interpretations for cannabis and hemp, depends on the Cabinet’s decision after reviewing the committee’s findings, taking into account the legal, socio-cultural, health, economy, Syariah law aspects and so on,” he further added to his statement.

Tags: Cannabis
Jasmine C.

Mabuhay! An upcoming Newswriter for the Asian Affairs from the Pearl of the Orient - Philippines. Avid follower of celebrity gossips, fashion news. I got into writing so that my fellow Kababayan will be constantly updated with the latest news.

Recent Posts

‘Yumi Cells Season 3’ Gearing Up With the Star-Studded Bombshell Cast!!

The most celebrated K-drama ‘Yumi Cells’ is returning back with its third season and fans can expect the excitement, fresh…

July 3, 2025

BLACKPINK Jennie BTS V Dating Rumors Spark Again

It seems that the K-pop world is in a run once again as Jennie, a member of BLACKPINK, and the…

July 3, 2025

Cricket South Africa Awards 2025: Date, Venue & Streaming Details

A prestigious celebration that honours the excellence of all levels of South African Cricket is ‘Cricket South Africa Awards 2025’…

July 3, 2025

Top 10 Drama of Amazon Prime Video in Japan. Who tops the list on July 1st week?

Everything in the world is running quick and fast-paced mode, the influence of the social media contents is also one…

July 3, 2025

A Heartwarming Drama ‘Love, Take Two’ Soon to be Launched in tvN

‘Love, Take Two’ is an upcoming K-drama which is set to premier on tvN, one of the leading broadcasters of…

July 3, 2025

MAS Plans Overhaul of Fund Liquidity Rules for Global Sync

Monetary Authority Of Singapore (MAS), the financial regulator of Singapore has said that it will update the liquidity risk management…

July 3, 2025